Harnessing innate lymphoid cells to boost the efficacy of immunotherapy in ovarian cancer

The University of Ottawa received a $299,760 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 15, 2025, with completion targeted for August 14, 2027. The award funds research focused on harnessing innate lymphoid cells to enhance immunotherapy efficacy in ovarian cancer treatment. This research initiative represents a translational investigation designed to generate novel therapeutic approaches and biomarker insights that advance both military health priorities and broader oncological treatment outcomes.

As a research-intensive Canadian institution with established federal grant management infrastructure, the University of Ottawa will conduct hypothesis-driven basic and applied research activities at its Ottawa, Ontario campus. The research delivery encompasses cellular mechanism investigation, therapeutic development, and scientific findings intended to support advancement of cancer immunotherapy solutions. This award aligns with the DHA's strategic emphasis on innovative cancer research and precision medicine approaches, with the two-year performance period allowing comprehensive investigation and documentation of research findings and technical developments.